Vascular Biogenics Ltd (NASDAQ:VBLT) has earned an average recommendation of “Hold” from the six research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $2.67.
VBLT has been the topic of several analyst reports. Oppenheimer initiated coverage on shares of Vascular Biogenics in a research report on Thursday, June 27th. They set an “outperform” rating and a $2.00 target price on the stock. CIBC began coverage on shares of Vascular Biogenics in a research note on Thursday, June 27th. They issued an “outperform” rating for the company. Zacks Investment Research cut shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research note on Thursday, August 29th. Chardan Capital reiterated a “hold” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research note on Tuesday, August 13th. Finally, ValuEngine upgraded shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.
Shares of NASDAQ VBLT traded up $0.02 during mid-day trading on Tuesday, reaching $1.28. The company had a trading volume of 8,680 shares, compared to its average volume of 15,124. Vascular Biogenics has a twelve month low of $0.60 and a twelve month high of $1.90. The company has a current ratio of 6.45, a quick ratio of 6.45 and a debt-to-equity ratio of 0.05. The stock’s 50 day moving average is $1.21 and its 200-day moving average is $1.34.
Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.25 million. Vascular Biogenics had a negative net margin of 3,021.20% and a negative return on equity of 35.35%. As a group, sell-side analysts anticipate that Vascular Biogenics will post -0.53 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Athena Capital Advisors LLC lifted its position in Vascular Biogenics by 216.7% in the 2nd quarter. Athena Capital Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock valued at $46,000 after acquiring an additional 23,950 shares in the last quarter. Morgan Stanley increased its stake in shares of Vascular Biogenics by 6.5% during the 2nd quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock worth $383,000 after purchasing an additional 17,900 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Vascular Biogenics by 66.7% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 37,500 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 15,000 shares during the last quarter. Finally, First Republic Investment Management Inc. increased its stake in shares of Vascular Biogenics by 7.4% during the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 5.38% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Story: How to calculate compound interest
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.